In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Unimed Pharmaceuticals

Latest From Unimed Pharmaceuticals

Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor

New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.

Deals Business Strategies

Chinook Will Soon Have $275m To Advance Kidney Disease Strategy

Chinook launched less than two years ago to develop precision medicines for chronic kidney diseases and will have three drugs in the clinic in 2021, including a Phase III candidate for IgA nephropathy.

Financing Renal

Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Financing Neurology

UK Consortium Given Go-Ahead For Rapid SARS-CoV-2 Antibody Test In Europe

UK-Rapid Test Consortium claims the CE marked, professional-use test is 99.4% accurate and plans to produce 500,000 tests a month from October and one million a month starting in 2021.

Europe Coronavirus COVID-19
See All

Company Information

UsernamePublicRestriction

Register